Anticoagulant Clinical Trial
Official title:
A Single Dose, Randomized, Open Label, Two-Treatment, Two-Sequence, Two-Period, Crossover Bioequivalence Study of WD-1602 Versus Pradaxa® in Healthy Subjects Under Fed Condition
This study will be a single-center, randomized, single-dose, open-label, two-treatment, two-period, two-sequence crossover bioequivalence study to compare the rate and extent of absorption of WD-1602 granule formulation (WD Pharma) to the reference drug Pradaxa® capsule (BI, Germany) under fed conditions in healthy subjects.
The study will comprise of a medical Screening visit, two 2-night (3-day) Treatment Periods, 2 outpatient visits, and a Follow-up visit. Each Treatment visit will be separated by a washout of up to 7 days. The Follow-up visit will occur approximately 7 days (±1) following the last study drug administration. The duration of subject participation, including screening, will be approximately 8 weeks. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04010955 -
Adding Antiplatelet During Edoxaban Treatment in Stroke Patients With Non-valvular Atrial Fibrillation (ADD-ON)
|
||
| Recruiting |
NCT04673695 -
A Clinical Study to Evaluate the Safety and Pharmacokinetics of CKD-344
|
Phase 1 | |
| Completed |
NCT03893591 -
A Prospective Study to Examine the Need to Adjust the Dose of Apixaban When Used in Atrial Fibrillation and Obesity
|
||
| Completed |
NCT03895502 -
Optimal Duration of Anticoagulation Therapy for Isolated Distal Deep Vein Thrombosis in Patients With Cancer Study
|
Phase 4 | |
| Completed |
NCT03154489 -
Effectiveness of a Multidisciplinary Medication Review With Follow-up for Patients Treated With Coumarin Anticoagulants in Primary Care
|
N/A | |
| Completed |
NCT04305821 -
Medico-economic Interest of the Protein S100b in Mild Head Trauma Under Anti-thrombotics
|
||
| Recruiting |
NCT06020560 -
Study of Low Molecular Weight Heparins
|
Phase 4 | |
| Not yet recruiting |
NCT05788913 -
Evaluation of the Pharmacodynamics of a Heparin With Its Biological Comparator, Subcutaneous Administration
|
Phase 1 | |
| Not yet recruiting |
NCT05788900 -
Evaluation of the Pharmacodynamics of a Heparin With Its Biological Comparator, Intravenous Administration
|
Phase 1 | |
| Terminated |
NCT03172546 -
Determinants of Oral Anticoagulants' Activity
|
||
| Recruiting |
NCT03772457 -
Predictive Value of Infarction Volume on Hemorrhagic Transformation in Ischemic Stroke/TIA With Non-valve Atrial Fibrillation(NVAF) Patients Using Rivaroxaban
|
||
| Completed |
NCT03323320 -
Evaluation of Patient's Knowledge of Their NACO Treatment
|
N/A | |
| Recruiting |
NCT04257487 -
Sulodexide, VESSEL®, for the Prevention of Recurrent Venous Thromboembolism (The Jason Study)
|
Phase 3 | |
| Completed |
NCT04272723 -
Management of Venous Thromboembolism in France: a National Survey Among Vascular Medicine Physicians
|
||
| Recruiting |
NCT04867200 -
A Clinical Study to Evaluate the Safety and Pharmacokinetics of CKD-344 in Healthy Volunteers
|
Phase 1 |